Sofosbuvir, Velpatasvir

Sofosbuvir and Velpatasvir are two powerful antiviral medications that work together to treat chronic hepatitis C, a viral infection that affects the liver. Sofosbuvir is an NS5B nucleotide polymerase inhibitor, while Velpatasvir is an NS5A replication complex inhibitor. Together, they target different stages of the hepatitis C virus (HCV) replication process, making it difficult for the virus to continue multiplying and causing harm to the liver.
The combination of Sofosbuvir and Velpatasvir is effective against a wide range of HCV genotypes and subtypes, making it a highly versatile treatment option. It is typically prescribed for patients with chronic hepatitis C who have not been previously treated or who have not responded well to other therapies. The medication is available in various formulations, including oral tablets and solutions, and is usually taken once daily for a duration of 12 weeks.
The primary goal of treatment with Sofosbuvir and Velpatasvir is to cure the infection, which is defined as undetectable HCV RNA in the blood at least 12 weeks after completing therapy. This results in significant improvements in liver function and a reduced risk of liver-related complications, such as cirrhosis, liver failure, and liver cancer. Additionally, the medication has been shown to have a favorable safety profile, with most side effects being mild and temporary.